When is the next results date for Guj. Themis Bio.?

No Upcoming Board Meetings

What is the bonus history of the Guj. Themis Bio.?

Gujarat Themis Biosyn Ltd announced a 1:2 bonus issue, with an ex-date of August 9, 2024, meaning shareholders will receive 1 additional share for every 2 shares held.

Gujarat Themis Biosyn Ltd has a recent bonus issue history where they announced a 1:2 bonus. The ex-date for this bonus is set for August 9, 2024. This means that for every 2 shares held, shareholders will receive 1 additional share. If you need further details or have more questions about the company, feel free to ask!

Has Guj. Themis Bio. declared dividend?

Gujarat Themis Biosyn Ltd has declared a 25% dividend, amounting to ₹0.25 per share, with an ex-date of July 15, 2024. The company has shown strong total returns over various periods, particularly impressive over the long term, despite recent fluctuations.

Gujarat Themis Biosyn Ltd has declared a 25% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 25%<BR>- Amount per share: 0.25<BR>- Ex-date: 15 Jul 24<BR><BR>Dividend Yield: 0.05%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -4.51%, the dividend return was 0%, resulting in a total return of -4.51%.<BR><BR>Over the past year, the price return was 24.43%, the dividend return was 0.09%, leading to a total return of 24.52%.<BR><BR>In the two-year period, the price return was 215.74%, the dividend return was 1.90%, culminating in a total return of 217.64%.<BR><BR>For the three-year period, the price return was 477.99%, the dividend return was 19.37%, resulting in a total return of 497.36%.<BR><BR>In the four-year span, the price return was 768.42%, the dividend return was 36.29%, which led to a total return of 804.71%.<BR><BR>Over the last five years, the price return was 1327.87%, the dividend return was 64.80%, resulting in a total return of 1392.67%.<BR><BR>Overall, Gujarat Themis Biosyn Ltd has declared a dividend while also showing significant total returns over various periods, particularly impressive over the longer term, indicating strong performance despite recent fluctuations.

Who are the peers of the Guj. Themis Bio.?

Guj. Themis Bio.'s peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Orchid Pharma, Panacea Biotec, IOL Chemicals, Novartis India, and Zota Health Care. Guj. Themis Bio. has average growth and management risk, with a 1-year return of 22.35%, higher than Orchid Pharma but lower than Panacea Biotec's 269.46%.

Peers: The peers of Guj. Themis Bio. are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Orchid Pharma, Panacea Biotec, IOL Chemicals, Novartis India, and Zota Health Care.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, and Guj. Themis Bio., while Average management risk is found at IOL Chemicals and Novartis India, and Below Average management risk is noted at Orchid Pharma, Panacea Biotec, and Zota Health Care. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is seen at Divi's Lab., Torrent Pharma, Guj. Themis Bio., Orchid Pharma, Panacea Biotec, and Zota Health Care, with Average growth at IOL Chemicals and Good growth at Novartis India. Excellent capital structure is held by Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, Guj. Themis Bio., IOL Chemicals, and Novartis India, while Good capital structure is found at Torrent Pharma, and Below Average capital structure is noted at Orchid Pharma, Panacea Biotec, and Zota Health Care.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Panacea Biotec at 269.46%, while the peer with the lowest is Orchid Pharma at -31.48%. Guj. Themis Bio.'s 1-year return of 22.35% is significantly higher than Orchid Pharma's but lower than Panacea Biotec's. Additionally, Orchid Pharma and Zota Health Care have negative six-month returns.

Is Guj. Themis Bio. overvalued or undervalued?

As of May 5, 2021, Guj. Themis Bio. is considered very expensive and overvalued with a PE Ratio of 72.45 and an EV to EBITDA of 51.24, significantly higher than competitors like Sun Pharma and Cipla, despite its impressive returns over the past three years.

As of 5 May 2021, the valuation grade for Guj. Themis Bio. moved from expensive to very expensive, indicating a significant increase in perceived valuation. The company is currently deemed overvalued. Key ratios include a PE Ratio of 72.45, an EV to EBITDA of 51.24, and a Price to Book Value of 15.82, all of which are substantially higher than industry peers. <BR><BR>In comparison, Sun Pharma has a PE Ratio of 35.25 and an EV to EBITDA of 24.91, while Cipla shows a PE Ratio of 22.99 and an EV to EBITDA of 15.93, highlighting that Guj. Themis Bio. is trading at a premium relative to these competitors. Additionally, despite its high returns over various periods, including a 511.99% return over three years compared to the Sensex's 49.20%, the elevated valuation metrics suggest that the stock may not be justified at its current price level.

Who are in the management team of Guj. Themis Bio.?

As of March 2023, the management team of Guj. Themis Bio. includes Dinesh S Patel (Chairman), Sachin D Patel, and four independent non-executive directors: Vijay Gopi Kishan Agarwal, Kirandeep Madan, Vikram D Sanghvi, and Siddharth Y Kusumgar.

As of March 2023, the management team of Guj. Themis Bio. includes the following individuals:<BR><BR>1. Dinesh S Patel - Chairman & Non Executive Director<BR>2. Sachin D Patel - Non Executive Director<BR>3. Vijay Gopi Kishan Agarwal - Independent Non Executive Director<BR>4. Kirandeep Madan - Independent Non Executive Director<BR>5. Vikram D Sanghvi - Independent Non Executive Director<BR>6. Siddharth Y Kusumgar - Independent Non Executive Director<BR><BR>These members play various roles within the company's board of directors.

What does Guj. Themis Bio. do?

Gujarat Themis Biosyn Ltd is a small-cap pharmaceutical and biotechnology company, incorporated in 1981 and currently owned by the Yuhan Group. As of March 2025, it reported net sales of ₹377 Cr and a net profit of ₹120 Cr, with a market cap of ₹4,045 Cr.

Overview: <BR>Gujarat Themis Biosyn Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Small Cap company.<BR><BR>History: <BR>The company was incorporated in 1981 and underwent a significant change in ownership in June 1991 when it was taken over by the Yuhan Group from South Korea and Pharmaceutical Business Group (India) Ltd. The most recent quarterly results reported net sales and net profit for March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 377 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 120 Cr (Quarterly Results - Mar 2025) <BR>Market cap: INR 4,045 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 83.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.05% <BR>Debt Equity: -0.03 <BR>Return on Equity: 21.83% <BR>Price to Book: 17.52 <BR><BR>Contact Details: <BR>Address: 69/C GIDC Industrial Estate, Valsad Dist VAPI Gujarat : 396195 <BR>Tel: 91-260-2430027 <BR>Email: accounts@gtbl.co.in/gtblmumbai@gtbl <BR>Website: http://www.gtbl.in

Who are the top shareholders of the Guj. Themis Bio.?

The top shareholders of Guj. Themis Bio include Pharmaceutical Business Group [India] Ltd with 47.02%, individual investors holding 19.31%, and foreign institutional investors at 2.51%. Additionally, mutual funds hold 1.16%, with Quant Mutual Fund - Quant Manufacturing Fund being the largest public shareholder at 1.15%.

The top shareholders of Guj. Themis Bio include the promoters, with the Pharmaceutical Business Group [India] Ltd holding the largest stake at 47.02%. Additionally, there are mutual funds involved, with five schemes collectively holding 1.16%, and foreign institutional investors (FIIs) holding 2.51% through ten different entities. The highest public shareholder is Quant Mutual Fund - Quant Manufacturing Fund, which has a holding of 1.15%. Individual investors also have a significant presence, owning 19.31% of the company.

How big is Guj. Themis Bio.?

As of 24th July, Gujarat Themis Biosyn Ltd has a market capitalization of 4,060.00 Cr, with Net Sales of 150.81 Cr and a Net Profit of 48.78 Cr for the latest four quarters. Shareholder's Funds are 201.38 Cr and Total Assets are 221.11 Cr as of March 2024.

As of 24th July, Gujarat Themis Biosyn Ltd has a market capitalization of 4,060.00 Cr, categorizing it as a Small Cap company.<BR><BR>For the latest four quarters, the company reported Net Sales of 150.81 Cr and a Net Profit of 48.78 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, with Shareholder's Funds amounting to 201.38 Cr and Total Assets of 221.11 Cr.

Are Guj. Themis Bio. latest results good or bad?

Gujarat Themis Biosyn's latest Q2 FY26 results are strong, with a net profit of ₹14.26 crores (up 34.92%) and record revenue of ₹42.35 crores (up 21.98%). The company also achieved a record operating margin of 49.47%, indicating robust performance in a challenging pharmaceutical environment.

Gujarat Themis Biosyn's latest results for Q2 FY26 are quite strong, indicating a positive performance. The company reported a net profit of ₹14.26 crores, which reflects a significant increase of 34.92% both quarter-on-quarter and year-on-year. Additionally, revenue grew by 21.98% on a year-on-year basis, reaching ₹42.35 crores, marking the highest quarterly sales figure in the company's history.<BR><BR>The operating margin also saw impressive growth, reaching 49.47%, the highest on record for the company, which underscores effective cost management and pricing power. Furthermore, the return on equity stands at a remarkable 34.65%, showcasing exceptional capital efficiency.<BR><BR>Overall, these results highlight a robust operational performance, especially in a challenging environment for the pharmaceutical sector. The company's ability to achieve substantial growth in both revenue and profit, along with record margins, suggests that the latest results are indeed good.

Should I buy, sell or hold Guj. Themis Bio.?

How has been the historical performance of Guj. Themis Bio.?

Guj. Themis Bio. experienced fluctuating net sales, reporting 150.80 Cr in Mar'25, down from 169.82 Cr in Mar'24 but up from 148.39 Cr in Mar'23. Profit metrics also declined, with profit after tax at 48.77 Cr in Mar'25, while total assets rose significantly to 301.31 Cr.

Answer:<BR>The historical performance of Guj. Themis Bio. shows a fluctuating trend in net sales and profitability over the years, with a notable increase in total operating income and profit margins in recent years.<BR><BR>Breakdown:<BR>Guj. Themis Bio. reported net sales of 150.80 Cr in Mar'25, a decrease from 169.82 Cr in Mar'24, but an increase from 148.39 Cr in Mar'23. The total operating income followed a similar pattern, peaking at 169.82 Cr in Mar'24 before declining to 150.80 Cr in Mar'25. The company's operating profit (PBDIT) was 71.27 Cr in Mar'25, down from 83.11 Cr in Mar'24, while profit before tax also decreased to 65.54 Cr from 79.33 Cr. Profit after tax for Mar'25 was reported at 48.77 Cr, a decline from 59.16 Cr in the previous year. The operating profit margin (excluding other income) was 45.65% in Mar'25, slightly down from 46.37% in Mar'24. Total assets increased significantly to 301.31 Cr in Mar'25 from 221.11 Cr in Mar'24, driven by a rise in total reserves to 237.49 Cr. The company also saw an increase in long-term borrowings to 29.64 Cr in Mar'25, compared to none in the previous year. Cash flow from operating activities improved to 91.00 Cr in Mar'25, up from 64.00 Cr in Mar'24, contributing to a net cash inflow of 5.00 Cr in Mar'25.

Is Guj. Themis Bio. technically bullish or bearish?

As of November 20, 2025, the trend is mildly bullish due to positive weekly MACD and KST signals, though caution is warranted from a mildly bearish weekly Dow Theory and lack of momentum in the RSI.

As of 20 November 2025, the technical trend has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by the weekly MACD and KST indicators showing bullish signals, while the daily moving averages also indicate a mildly bullish trend. However, the weekly Dow Theory is mildly bearish, which adds some caution. The RSI shows no signal on both weekly and monthly timeframes, suggesting a lack of momentum. Overall, the strength of the bullish stance is tempered by mixed signals from other indicators.

Which are the latest news on Guj. Themis Bio.?

Why is Guj. Themis Bio. falling/rising?

As of 03-Dec, Gujarat Themis Biosyn Ltd's stock price is rising to 399.90, reflecting a year-to-date increase of 30.92% and strong long-term growth potential, despite a recent weekly decline. The company shows high management efficiency and financial stability, contributing to a positive outlook for the stock.

As of 03-Dec, Gujarat Themis Biosyn Ltd's stock price is rising, currently at 399.90, with a change of 0.65 (0.16%) upward. This increase can be attributed to several factors. Despite a recent decline of 4.05% over the past week, the stock has shown strong performance year-to-date, with a remarkable increase of 30.92%, significantly outperforming the Sensex, which has risen by only 8.92% in the same period. Additionally, the stock has demonstrated consistent returns over the last three years, with a staggering 270.02% increase, indicating strong long-term growth potential.<BR><BR>Moreover, the company exhibits high management efficiency, reflected in its return on equity (ROE) of 32.79%, and maintains a low debt-to-equity ratio of 0.05 times, suggesting financial stability. Although there has been a slight decline in investor participation, with a 3.07% drop in delivery volume compared to the 5-day average, the stock remains liquid enough for trading. The current price performance is also in line with the sector, which may contribute to investor confidence. Overall, these factors indicate a positive outlook for the stock, contributing to its rising price.